Nevertheless, Kunde and colleagues [20] reported that the new ALT standard proposed by Prati and colleagues [19] may be helpful for early recognition of the milder spectrums of NAFLD but may result in significant healthcare expenditure and questionable benefit. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.